Type 1 diabetes management is entering a new phase as the NHS begins implementing a treatment approach that extends beyond traditional insulin therapy. The disease has been managed with insulin for over a century, but a recently developed intervention is now being deployed across the health service with the potential to postpone disease onset by several years.
The new treatment, teplizumab, is being offered to patients identified through expanded screening programs. One patient, Dima, and his mother Elena shared their experience after he tested positive for markers indicating future type 1 diabetes development. Dima participated in a trial of the drug, providing insight into what the treatment process involves for patients and families facing a diagnosis.
Experts from leading institutions are highlighting how these developments represent a fundamental shift in disease management. Parth Narendran, a professor of diabetes medicine at the University of Birmingham, and Dr. Renuka Dias, a consultant paediatric endocrinologist at Birmingham Women’s and Children’s Hospital, have detailed how the changes are reshaping clinical practice and patient outcomes. The combination of proactive screening and new pharmaceutical options is changing the landscape of type 1 diabetes care.
The rollout reflects broader efforts to prevent or delay disease progression rather than simply managing symptoms after diagnosis. As screening programs identify individuals at risk earlier, treatment protocols are being adjusted to intervene before symptoms fully manifest, potentially improving long-term health trajectories for patients.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI